News & Events

  • April 26, 2013
      Congratulations to Dr. Michael Law, winner of the UBC Faculty of Medicine Distinguished Achievement Award for Overall Excellence - Early Career.   Dr. Law was very successful in terms of knowledge translation and policy impact from his work on generic drug prices. As a result of his opinion piece on the high generic drug prices in Canada, he met with then BC Minister of Health... Read More
  • April 17, 2013
      Paying for Hospital Services: A Hard Look at the Options An April 2013 report by Jason Sutherland, Trafford Crump, Nadya Repin, and Erik Hellsten published by the CD Howe Institute finds activity-based funding is a viable complement to fixed annual lump sum budgets for rebalancing the financial incentives for Canadian hospitals.
  • April 4, 2013
      Congratulations to CHSPR PhD student Ruth Lavergne on the receipt of the 2012/13 Margaret Fulton Award. This annual award is given to an individual who has had a significant positive impact on student life and student development at UBC.
  • February 22, 2013
      What, If Anything, Does Amenable Mortality Tell Us about Regional Health System Performance? Ruth Lavergne and Kimberlyn McGrail   Money Left on the Table: Generic Drug Prices in Canada          Michael R. Law
  • February 13, 2013
      On February 8, 2013, CHSPR faculty and staff lost a close friend and colleague, Clyde Hertzman. While, deservedly, much has already been written about Clyde’s path-breaking contributions to the world’s understanding of the influence of the “early years” on individuals’ life courses, the breadth of his scholarship, and particularly his many years of... Read More
  • November 23, 2012
    By Kimberlyn McGrail Published in The Lancet, November 17, 2012   Paul Webster's World Report, “Can Canada reckon with its health costs?” (Sept 8, p 875) (1) suggests that our ageing population is putting the main financial strain on the Canadian health-care system. The story states that caring for increasing numbers of elderly patients with expensive-to-treat... Read More
  • November 23, 2012
    Pharmacare 2020 is a stimulating, national symposium conceived to promote clarity about the future of prescription drug coverage in Canada. The conference will feature a diverse range of thought-provoking speakers and will showcase sponsor exhibits and research posters. The website offers information about the program and registration, and also features videos that we hope will spark a national... Read More
  • November 23, 2012
    By Margaret J. McGregor and Danielle Martin Published in Canadian Family Physician, November 2012 Health care costs are rising in Canada, and not mainly because of population aging. One of the fastest growing areas of health services spending is laboratory testing. Laboratory tests are not free. McGrail and colleagues recently demonstrated that in British Columbia (BC), $174... Read More
  • November 7, 2012
    By Michael Law Published in the Toronto Star, November 4, 2012 Generic drug companies often present themselves as a modern-day Robin Hood: taking from brand name drug companies, and passing the spoils on to Canadians. Public debate is brewing, however, over how to split the loot. Recently, the Canadian Generic Pharmaceutical Association (CGPA) released a report on the “risks... Read More
  • September 28, 2012
    By Michael Law Published in the Toronto Star, September 27, 2012 Would you pay $60 for a large coffee at Tim Hortons? How about $500,000 for a Toyota Corolla? You probably wouldn’t, but consider this: compared to other countries, this is how inflated Canadian prices are for some generic prescription drugs. That our generic drug prices are high is no great secret, and recently nearly... Read More

Pages